Novel tricyclic compounds as inhibitors of mutant idh enzymes

A compound of formula (I):

• wherein A is —C(R1)═ or —N═, and R1 is hydrogen or hydroxyl;
• X is a bridged ring moiety selected from the group consisting of:
• B is —C(R10)— or —N—;
• a is 0 or 1;
• b is 0 or 1;
• m is 0, 1 or 2;
• p is 0 or 1;
• r is 0, 1 or 2;
• with the proviso that when r is 2, m is 0;
• R is selected from the group consisting of:
• (1) halogen,
• (2) —CN, and
• (3) —(C═O)t—Ra, wherein t is 0 or 1;
• each occurrence of R2, R3, R4, R5, R6, R7, R11, R12, R13, R14 and R15 is independently selected from the group consisting of:
• (1) halogen,
• (2) —CN, and
• (3) —(C═O)t—Ra, wherein t is 0 or 1;
• R8 is selected from the group consisting of:
• (1) hydrogen,
• (2) —CN, and
• (3) C1-6alkyl;
• R9 is selected from the group consisting of:
• (1) halogen,
• (2) —CN, and
• (3) —(C═O)t-Ra, wherein t is 0 or 1;
• R10 is hydrogen or C1-6alkyl;
• each occurrence of Ra is independently selected from the group consisting of:
• (1) hydrogen,
• (2) —(O)t—Rd, wherein t is 0 or 1;
• Rd is selected from the group consisting of (a) hydrogen, (b) C1-6alkyl, (c) C3-7cycloalkyl, and (d) phenyl;
• wherein each of the C1-6alkyl of (b) and C3-7cycloalkyl of (c) is optionally substituted with one to four substituents independently selected from Rb,
• (3) —NRxRy, wherein each of Rx and Ry is independently selected from the group consisting of (a) hydrogen, (b) C1-6alkyl, (c) C3-6cycloalkyl, (d) —O—C1-6alkyl, (e) phenyl optionally substituted with one to four halogens, and (f) heterocyclyl;
• wherein the C1-6alkyl of (b) is optionally substituted with one to four substituents independently selected from halogen, —O—C1-4alkyl, C3-6cycloalkyl, and
• heterocyclyl;
• and
• the C3-6cycloalkyl of (c) is optionally substituted with one to four substituents independently selected from halogen, —O—C1-4alkyl, C3-6cycloalkyl, heterocyclyl, and C1-4alkyl, which is optionally substituted with one to four halogens, the heterocyclyl of (f) is optionally substituted with one to four substituents independently selected from halogen, C1-4alkyl, —O—C1-4alkyl, C3-6cycloalkyl, and heterocyclyl,
• (4) C2-6alkenyl, optionally substituted with one to four substituents independently selected from Rb,
• (5) C5-6cycloalkenyl, optionally substituted with one to four substituents independently selected from Rb,
• (6) aryl, optionally substituted with one to four substituents independently selected from Rb, and
• (7) heterocyclyl, optionally substituted with one to four substituents independently selected from Rb;
• each occurrence of Rb is independently selected from the group consisting of:
• (1) halogen,
• (2) —CN,
• (3) oxo,
• (4) —(O)t—Rd, wherein t is 0 or 1;
• Rd is selected from the group consisting of (a) hydrogen, (b) C1-6alkyl, (c) C3-7cycloalkyl, and (d) heterocyclyl;
• wherein the C1-6alkyl of (b) is optionally substituted with one to four substituents independently selected from (i) halogen, (ii) hydroxyl, (iii) —O—C1-6alkyl, (iv) C3-6cycloalkyl optionally substituted with 1-3 halogens, (v) —NRxRy, wherein each of Rx and Ry is independently selected from the group consisting of hydrogen, C1-6 alkyl, C3-6cycloalkyl, phenyl optionally substituted with one to four halogens, and heterocyclyl, and (vi) heterocyclyl;
• the C3-7cycloalkyl of (c) is optionally substituted with one to four substituents independently selected from (i) halogen, and (ii) C1-6alkyl, which is optionally substituted with one to four halogens, and (iii) —CN;
• and
• the heterocyclyl of (d) is optionally substituted with one to four substituents independently selected from (i) halogen, (ii) hydroxyl, (iii) oxo, (iv) C1-6alkyl optionally substituted with one to four halogens, (v) —O—C1-6alkyl, (vi) heterocyclyl optionally substituted with halogen or hydroxyl, and (vii) —NRjRk;
• wherein each of Rj and Rk is independently selected from the group consisting of hydrogen and C1-6alkyl,
• (5) —(C═O)t—Rc, wherein t is 0 or 1;
• Rc is selected from the group consisting of hydrogen, hydroxyl, C1-6alkyl, C2-6alkenyl, —O—C1-6alkyl, —NRxRy, and heterocyclyl;
• wherein each of Rx and Ry is independently selected from the group consisting of (a) hydrogen, (b) C1-6alkyl, (c) C2-6alkenyl, (d) C3-6cycloalkyl, (e) phenyl optionally substituted with one to four halogens, and (f) heterocyclyl;
• wherein the C1-6alkyl of (b) is optionally substituted with one to four substituents independently selected from halogen, —O—C1-4alkyl, C3-6cycloalkyl, heterocyclyl, and —(C═O)—NRjRk, wherein each of Rj and Rk is independently hydrogen or C1-6 alkyl,
• the C3-6cyclolkyl of (d) is optionally substituted with one to four substituents independently selected from halogen and C1-4alkyl, which is optionally substituted with one to four halogens, and
• the heterocyclyl of (f) is optionally substituted with one to four substituents independently selected from halogen, —CN, C1-6alkyl, and —O—C1-6alkyl,
• (6) C2-6alkenyl, and
• (7) phenyl, optionally substituted with one to four substituents independently selected from halogen, C1-6alkyl, and —O—C1-6alkyl;
• or a pharmaceutically acceptable salt thereof.